SRPT Q1 2021 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$147M+29.3% YoY

Gross Profit

$125M84.8% margin

Operating Income

-$152M-103.4% margin

Net Income

-$167M-113.8% margin

EPS (Diluted)

$-2.10

QoQ Revenue Growth

+1.2%

Cash Flow

Operating Cash Flow

-$180M

Free Cash Flow

-$202M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$2.8B

Total Liabilities

$2.2B

Stockholders' Equity

$535M

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$147M	$114M	+29.3%
Gross Profit	$125M	$101M	+23.3%
Operating Income	-$152M	-$118M	-28.7%
Net Income	-$167M	-$17M	-856.2%

Revenue Segments

E X O N D Y S Fifty One

$107M86%

V Y O N D Y S Fifty Three

$18M14%

A M O N D Y S Fourty Five

$193,0000%